Patents by Inventor George Vasmatzis
George Vasmatzis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11866789Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.Type: GrantFiled: August 25, 2021Date of Patent: January 9, 2024Assignee: The Translational Genomics Research InstituteInventors: Sara Byron, Jessica Aldrich, John Carpten, David Craig, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
-
Patent number: 11845084Abstract: Provided are methods and related devices for preparing a cell and tissue culture, including a hanging drop culture. Microwells are specially loaded with cell mixtures using a removable reservoir and forcing cells into the underlying microwells. The removable reservoir is removed and the cells partitioned into the individual microwells and covered by an immiscible layer of fluid. The microwells and immiscible layer is inverted and the cells in the microwells cultured. The microwells may have shape-controlling elements to control the three-dimensional shape of the culture.Type: GrantFiled: May 4, 2021Date of Patent: December 19, 2023Assignees: The Board of Trustees of the University of Illinois, Mayo Foundation for Medical Education and ResearchInventors: Anurup Ganguli, Rashid Bashir, Panagiotis Z. Anastasiadis, George Vasmatzis
-
Publication number: 20220042112Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.Type: ApplicationFiled: August 25, 2021Publication date: February 10, 2022Applicants: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Sara Byron, Jessica Aldrich, John Carpten, David Craig, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
-
Patent number: 11186875Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.Type: GrantFiled: June 13, 2016Date of Patent: November 30, 2021Assignees: The Translational Genomics Research Institute, Mayo Foundation for Medical Education and ResearchInventors: John Carpten, David Craig, Sara Byron, Jessica Aldrich, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
-
Publication number: 20210339244Abstract: Provided are methods and related devices for preparing a cell and tissue culture, including a hanging drop culture. Microwells are specially loaded with cell mixtures using a removable reservoir and forcing cells into the underlying microwells. The removable reservoir is removed and the cells partitioned into the individual microwells and covered by an immiscible layer of fluid. The microwells and immiscible layer is inverted and the cells in the microwells cultured. The microwells may have shape-controlling elements to control the three-dimensional shape of the culture.Type: ApplicationFiled: May 4, 2021Publication date: November 4, 2021Inventors: Anurup GANGULI, Rashid BASHIR, Panagiotis Z. ANASTASIADIS, George VASMATZIS
-
Patent number: 10494677Abstract: This document provides methods and materials related to assessing prostate cancer in mammals. For example, this document provides nucleic acids and polypeptides that can be analyzed to determine whether a male mammal having prostate cancer is susceptible to a good or poor outcome.Type: GrantFiled: December 14, 2016Date of Patent: December 3, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: George Vasmatzis, John C. Cheville, Farhad Kosari, Cemile D. Savci-Heijink, Eric W. Klee, Jan Marie A. Willard, Lori S. Tillmans
-
Patent number: 10203330Abstract: This document provides methods and materials involved in identifying mammals having lung adenocarcinoma characterized by neuroendocrine differentiation as well as methods and materials involved in treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation. For example, methods and materials for using ASCL1 and RET expression levels to identify lung cancer patients having lung adenocarcinoma characterized by neuroendocrine differentiation are provided.Type: GrantFiled: March 10, 2017Date of Patent: February 12, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: Farhad Kosari, George Vasmatzis, Marie-Christine Aubry, Cristiane M. Ida
-
Publication number: 20180171412Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.Type: ApplicationFiled: June 13, 2016Publication date: June 21, 2018Inventors: John Carpten, David Craig, Sara Byron, Jessica Aldrich, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
-
Publication number: 20170285034Abstract: This document provides methods and materials involved in identifying mammals having lung adenocarcinoma characterized by neuroendocrine differentiation as well as methods and materials involved in treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation. For example, methods and materials for using ASCL1 and RET expression levels to identify lung cancer patients having lung adenocarcinoma characterized by neuroendocrine differentiation are provided.Type: ApplicationFiled: March 10, 2017Publication date: October 5, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: Farhad Kosari, George Vasmatzis, Marie-Christine Aubry, Cristiane M. Ida
-
Patent number: 9677137Abstract: This document provides methods and materials involved in detecting translocations of TBL1XR1 and TP63 nucleic acid. For example, methods and materials for detecting TBL1XR1 and TP63 gene rearrangements (e.g., translocations) associated with cancer (e.g., T-cell lymphomas) as well as methods and materials for detecting cancers (e.g., T-cell lymphomas) with a dominant negative TP63 phenotype are provided.Type: GrantFiled: February 27, 2013Date of Patent: June 13, 2017Assignee: Mayo Foundation for Medical Education and ResearchInventors: George Vasmatzis, Andrew L. Feldman, Sarah H. Johnson, Rhett P. Ketterling, Ryan A. Knudson, Kathryn E. Pearce, Julie C. Porcher
-
Publication number: 20170159131Abstract: This document provides methods and materials related to assessing prostate cancer in mammals. For example, this document provides nucleic acids and polypeptides that can be analyzed to determine whether a male mammal having prostate cancer is susceptible to a good or poor outcome.Type: ApplicationFiled: December 14, 2016Publication date: June 8, 2017Inventors: George Vasmatzis, John C. Cheville, Farhad Kosari, Cemile D. Savci-Heijink, Eric W. Klee, Jan Marie A. Willard, Lori S. Tillmans
-
Publication number: 20170022546Abstract: Provided are methods and systems for characterizing a biomolecular parameter of a polynucleotide. A polynucleotide of interest from a sample comprising a heterogeneous mixture of polynucleotides is concentrated and provided to a first fluid compartment of a solid-state nanopore. An electric potential is established across the solid-state nanopore to force the polynucleotide of interest from a first fluid compartment to a second fluid compartment via the nanopore. A passage parameter output is monitored during passage of the polynucleotide of interest through the nanopore, wherein the passage parameter output depends on the biomolecular parameter status of the polynucleotide of interest. In this manner, the methods and systems are compatible with a wide range of applications, including epigenetic modifications to DNA indicative of a disease state such as cancer, in an integrated, reliable and low cost system.Type: ApplicationFiled: March 10, 2015Publication date: January 26, 2017Inventors: Rashid BASHIR, Bala Murali VENKATESAN, George VASMATZIS, Jiwook SHIM
-
Patent number: 9534249Abstract: This document provides methods and materials related to assessing prostate cancer in mammals. For example, this document provides nucleic acids and polypeptides that can be analyzed to determine whether a male mammal having prostate cancer is susceptible to a good or poor outcome.Type: GrantFiled: November 30, 2012Date of Patent: January 3, 2017Assignee: Mayo Foundation for Medical Education and ResearchInventors: George Vasmatzis, John C. Cheville, Farhad Kosari, Cemile D. Savci-Heijink, Eric W. Klee, Jan Marie A. Willard, Lori S. Tillmans
-
Publication number: 20160018399Abstract: This document provides methods and materials involved in identifying mammals having lung adenocarcinoma characterized by neuroendocrine differentiation as well as methods and materials involved in treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation. For example, methods and materials for using ASCL1 and RET expression levels to identify lung cancer patients having lung adenocarcinoma characterized by neuroendocrine differentiation are provided.Type: ApplicationFiled: March 7, 2014Publication date: January 21, 2016Inventors: Farhad Kosari, George Vasmatzis, Marie-Christine Aubry, Cristiane M. Ida
-
Publication number: 20150191789Abstract: This document provides methods and materials related to identifying prostate cancer in male mammals. For example, methods and materials for assessing a benign prostate sample (e.g., benign prostate tissue or cells) to determine whether or not a mammal has prostate cancer are provided.Type: ApplicationFiled: February 6, 2013Publication date: July 9, 2015Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Farhad Kosari, John C. Cheville, R. Jeffrey Karnes, George Vasmatzis
-
Publication number: 20150037796Abstract: This document provides methods and materials involved in detecting translocations of TBL1XR1 and TP63 nucleic acid. For example, methods and materials for detecting TBL1XR1 and TP63 gene rearrangements (e.g., translocations) associated with cancer (e.g., T-cell lymphomas) as well as methods and materials for detecting cancers (e.g., T-cell lymphomas) with a dominant negative TP63 phenotype are provided.Type: ApplicationFiled: February 27, 2013Publication date: February 5, 2015Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: George Vasmatzis, Andrew L. Feldman, Sarah H. Johnson, Rhett P. Ketterling, Ryan A. Knudson, Kathryn E. Pearce, Julie C. Porcher
-
Publication number: 20150024420Abstract: This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein.Type: ApplicationFiled: October 7, 2014Publication date: January 22, 2015Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: George G. Klee, George Vasmatzis, Farhad Kosari, Eric W. Klee
-
Patent number: 8871451Abstract: This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein.Type: GrantFiled: September 7, 2012Date of Patent: October 28, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventors: George G. Klee, George Vasmatzis, Farhad Kosari, Eric W. Klee
-
Patent number: 8679743Abstract: This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells are provided. This document also relates to reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas. For example, methods and materials involved in reducing the expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells and identifying agents having the ability to reduce expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells are provided.Type: GrantFiled: August 19, 2011Date of Patent: March 25, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventors: Andrew L. Feldman, Ahmet Dogan, George Vasmatzis, Mark Law, David I. Smith
-
Publication number: 20130302808Abstract: This document provides methods and materials related to assessing prostate cancer in mammals. For example, methods and materials for using ERG expression levels and TOP2A expression levels to identify mammals (e.g., male human patients) as being susceptible to a poor prostate cancer outcome are provided.Type: ApplicationFiled: July 12, 2011Publication date: November 14, 2013Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: George Vasmatzis, John C. Cheville, R. Jeffrey Karnes, Cristiane M. Ida, Jan Marie A. Willard